Terms: = Endocrine gland cancer AND OMD, osteoadherin, 4958, ENSG00000127083, Q99983, SLRR2C
8 results:
1. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.
Leonhardt CS; Stamm T; Hank T; Prager G; Strobel O
ESMO Open; 2023 Dec; 8(6):102067. PubMed ID: 37988953
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy of endoscopic ultrasound-guided tissue acquisition for solid pancreatic lesions 20 mm or less in diameter suspected as neuroendocrine tumors or requiring differentiation.
Kawasaki Y; Hijioka S; Nagashio Y; Maruki Y; Ohba A; Takeshita K; Takasaki T; Agarie D; Hagiwara Y; Hara H; Okamoto K; Yamashige D; Kondo S; Morizane C; Ueno H; Mizui T; Takamoto T; Nara S; Ban D; Esaki M; Tamada K; Hiraoka N; Saito Y; Okusaka T
J Gastroenterol; 2023 Jul; 58(7):693-703. PubMed ID: 37154933
[TBL] [Abstract] [Full Text] [Related]
3. Proposal for a definition of "Oligometastatic disease in pancreatic cancer".
Damanakis AI; Ostertag L; Waldschmidt D; Kütting F; Quaas A; Plum P; Bruns CJ; Gebauer F; Popp F
BMC Cancer; 2019 Dec; 19(1):1261. PubMed ID: 31888547
[TBL] [Abstract] [Full Text] [Related]
4. Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma.
Gemenetzis G; Groot VP; Blair AB; Ding D; Thakker SS; Fishman EK; Cameron JL; Makary MA; Weiss MJ; Wolfgang CL; He J
J Surg Oncol; 2018 Dec; 118(8):1277-1284. PubMed ID: 30380143
[TBL] [Abstract] [Full Text] [Related]
5. Pathologic Risk Factors for Metastatic Disease in Postpubertal Patients With Clinical Stage I Testicular Stromal Tumors.
Rove KO; Maroni PD; Cost CR; Fairclough DL; Giannarini G; Harris AK; Schultz KA; Cost NG
Urology; 2016 Nov; 97():138-144. PubMed ID: 27538802
[TBL] [Abstract] [Full Text] [Related]
6. Pathologic Risk Factors in Pediatric and Adolescent Patients With Clinical Stage I Testicular Stromal Tumors.
Rove KO; Maroni PD; Cost CR; Fairclough DL; Giannarini G; Harris AK; Schultz KA; Cost NG
J Pediatr Hematol Oncol; 2015 Nov; 37(8):e441-6. PubMed ID: 26479987
[TBL] [Abstract] [Full Text] [Related]
7. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
[TBL] [Abstract] [Full Text] [Related]
8. Common malignancy-associated regions of transcriptional activation (MARTA) in human prostate, breast, ovarian, and colon cancers are targets for DNA amplification.
Glinsky GV; Ivanova YA; Glinskii AB
Cancer Lett; 2003 Nov; 201(1):67-77. PubMed ID: 14580688
[TBL] [Abstract] [Full Text] [Related]
